NeuroMab™ Anti-ERBB2 BBB Shuttle Antibody(NRZP-1022-ZP3414)

Figure 1 demonstrates the specificity of the HtrA3 mAb.

Equal amounts (50 ng) of recombinant (r) human HtrA proteins [rHtrA1 (A1), rHtrA2 (A2) and rHtrA3 (A3, HtrA3-L-S305A)] were separated on a reducing 12% SDS-PAGE gel and analyzed using Western blot using HtrA3 mAbs (6G6, 9C9, 2C4, 1OH10 and 3E6), anti-HtrA1 and anti-HtrA2 antibodies, respectively.

Figure 2 shows Western blot analysis of protein lysates from human and mouse reproductive tissue using HtrA3 mAb.

Lysates from human trophoblast cell line HTR8 (HTR8) and human endometrial tissues of the mid proliferative (MP) and mid-secretory (MS) phases of the menstrual cycle were probed with 30 mAbs 6G6, 2C4, 1OH10 and 3E6.

Figure 3 shows the immunohistochemical analysis of HtrA3 protein in human and mouse reproductive tissues using HtrA3 mAb.

Representative images of immunostaining in human endometrial tissues from the mid-proliferative (MP, A and C) and mid-secretory (MS, B and D) phases of the menstrual cycle with mAbs 6G6 (A and B) and 1 OH 10 (C and D). Representative 5 images of immunostaining in mouse embryo implantation sites on d10.5 (E) and d13.5 (F) of pregnancy with mAb 3E6.

Figure 4 illustrates the optimization and validation of HtrA3 AlphaLISA.

(A) Detecting equal amounts (50 pM) of HtrA3, HtrA2, HtrA1, or BSA, or measuring HtrA3 (50 pM) when biotinylated irrelevant antibody (irrelevant mAb) was substituted for biotinylated 20 HtrA3 mAb or in the absence of donor beads . (B) Analysis of equal amounts of HtrA3 (50 pM) and different concentrations of biotinylated mAb to determine subhook points.

Figure 5 shows the real-time progressive curves of HtrA3 substrate hydrolysis in the presence of 50ug/ml of individual HtrA3 mAbs (6G6, 9C9, 2C4, 10H10, and 3E6) or a control mAb.